Physician profile
Samuel Mayeda
NPI 1487716544
$10,913.36
in general payments reported to CMS, 2019-2025
47 companies · $551 in 2025
The $551 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,572 · 2020: $2,156 · 2021: $1,894 · 2022: $1,500 · 2023: $1,276 · 2024: $965 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,875.65 | 2019-2025 | Repatha, Prolia, Evenity |
| Lilly USA, LLC | $1,334.72 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Ibsa Pharma INC. | $738.09 | 2019-2025 | Tirosint, Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $696.96 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $681.20 | 2019-2025 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $679.89 | 2019-2024 | |
| Novo Nordisk INC | $556.03 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Mannkind Corporation | $494.38 | 2019-2022 | |
| Abbvie INC. | $382.18 | 2019-2025 | |
| Esperion Therapeutics, INC. | $379.02 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $273.60 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $248.46 | 2021-2024 | Strensiq |
| Abbott Laboratories | $208.30 | 2019-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $205.79 | 2019-2022 | |
| Insulet Corporation | $205.03 | 2019-2025 | Omnipod |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Mayeda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.